A Pilot Study of Pazopanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Pazopanib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 13 Jul 2020 Status changed from active, no longer recruiting to discontinued.
- 14 Feb 2020 Planned End Date changed from 31 Dec 2019 to 31 Oct 2020.
- 14 Feb 2020 Planned primary completion date changed from 31 Dec 2019 to 31 Oct 2020.